NR1H4 and metabolic disease: Dietary and drug interventions can regulate the abundance of BSH-secreting gut microbiota and these strategies can modulate BA deconjugation and levels of the endogenous FXR antagonists glycoursodeoxycholic acid (GUDCA), tauroursodeoxycholic acid (TUDCA), and tauro-β-muricholic acid (TβMCA), which contributes to an improvement in metabolic diseases.